Last updated on May 2018

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.


Brief description of study

Rollover study supporting solid tumor and hematological disorder indications from Celgene sponsored CC-486 protocols eligible for participation in the study.

Detailed Study Description

The open-label, multicenter, multinational rollover study is intended to evaluate the safety of CC-486, while providing continued treatment with CC-486 for subjects who are receiving single agent CC-486 at the time of transition to the rollover study and tolerated the protocol prescribed regimen in Celgene-sponsored trials, and whom in the opinion of the Investigator may derive clinical benefit from continuing treatment with CC-486. Subjects' survival will also be followed if required by the parent CC-486 study protocol. If approved by Celgene, subjects from any ongoing or future Celgene sponsored CC-486 studies in solid tumors and hematological disorders will be included in this protocol.

Clinical Study Identifier: NCT02494258

Contact Investigators or Research Sites near you

Start Over

Associate Director Clinical Trial Disclosure

University of Florida College of Med
Gainesville, FL United States
  Connect »

Associate Director Clinical Trial Disclosure

Johns Hopkins Oncology Center
Baltimore, MD United States
  Connect »

Associate Director Clinical Trial Disclosure

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Associate Director Clinical Trial Disclosure

Virginia Oncology Associates
Norfolk, VA United States
  Connect »